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The octanoylated peptide hormone ghrelin regulates episodic growth hormone release and energy balance.
Work in genetically modifiedmice (Kirchner et al., 2009) now shows that in vivo activity of ghrelinO-acyltrans-
ferase (GOAT), responsible for ghrelin octanoylation, decreases during fasting but increases after ingesting
medium-chain fatty acid triglycerides (MCT).Identification of an orphan receptor (GHS-
R1a) that mediates the action of synthetic
molecules designed to rejuvenate the
growth hormone (GH) axis in elderly
humans subsequently led to identification
of a natural GHS-R1a agonist called
ghrelin (Smith et al., 1997; Kojima et al.,
1999). Ghrelin is an octanoylated 28-
residue peptide that modulates important
physiological functions, including appe-
tite, glucose homeostasis, aging of the
GH axis, immune function, and energy
balance. Without the octanoate modifica-
tion on serine-3, the ghrelin peptide
neither binds to nor activates its receptor
(GHS-R1a); at this time, noother biological
function has been ascribed to this unique
modification. All attempts to increase
ghrelin levels by overexpressing the
ghrelin gene (Ghrl) in transgenic mice
produced high levels of des-acyl ghrelin
(DAG) without increasing active ghrelin;
hence, the in vivo concentration of the
acylating enzyme appeared rate limiting.
Last year, two groups independently
identified the acyltransferase that selec-
tively esterifies DAG to produce ghrelin
(Yang et al., 2008; Gutierrez et al., 2008).
The enzyme MBOAT4, or ghrelin O-acyl-
transferase (GOAT), is 1 of a 16 member
family of membrane-bound O-acyltrans-
ferases (MBOATs). New work from
Kirschner et al. extends these findings by
demonstrating in genetically modified
mice that ghrelin production in vivo is
dependent upon the concentration of
Mboat4 and that food intake regulates
Mboat4 expression.
The investigators first askedwhat effect
feeding and fasting (12–36 hr) would have
on Mboat4 and Ghrl gene expression.
Intriguingly, expression of Mboat4 was
found to be highest during ad lib feeding
and declined to a minimum following
a 12 hr fast. This was a surprise because82 Cell Metabolism 10, August 6, 2009 ª2009ghrelin levels surge shortly before
a meal, and it was anticipated that GOAT
expression would parallel ghrelin secre-
tion. An increase in DAG/ghrelin ratio
accompanied fasting, consistent with
the reduction in Mboat4 mRNA levels.
The increase in Mboat4 expression
following ingestion of food explains the
delay in observing increases in circulating
ghrelin after the first meal following a fast.
In fasted mice that were fed the GOAT
substrate glyceryl trioctanoate, 3 hr
passed before active ghrelin was signifi-
cantly increased in the stomach (Nishi
et al., 2005).
Based on reports that ghrelin adminis-
tration increases food intake and fat accu-
mulation in rodents, the authors tested
whether Mboat4/ mice, which cannot
produce active ghrelin, are resistant to
diet-inducedobesity.Duringad lib feeding,
Mboat4/ mice and wild-type mice
consumed identical amounts of normal
chowand exhibited identical bodyweights
and body composition. Similarly, when fed
a high-fat diet for 8 weeks, theMboat4/
mice again exhibited food intake and
body composition identical to wild-types.
Although the lack of resistance to diet-
induced obesity may seem surprising, it is
consistent with results from studies in con-
genic ghrelin/ and Ghsr/ mice that
were fed normal chow and high-fat diets
(Sun et al., 2008). However, when wild-
type and Mboat4/ mice were fed a diet
enriched in MCT, wild-type mice ate less,
became heavier, and deposited more fat
compared to Mboat4/ mice. This result
indicates that inhibiting fat accumulation
by blocking ghrelin action is highly depen-
dent upon composition of the diet, and
medium-chain fatty acid triglycerides play
a unique role.
To investigate the effects of producing
supraphysiologic levels of ghrelin, trans-Elsevier Inc.genicmice (Tg)weregeneratedcontaining
human GHRL and humanMBOAT4 under
the control of the human APOE promoter
in the liver. Surprisingly, these mice did
not produce active human ghrelin (GHRL)
until they were fed a diet supplemented
with MCT. On the MCT diet, the Tg mice
produced 30-fold higher levels of active
human GHRL compared to levels of
endogenous mouse Ghrl in wild-type
mice. This resulted in higher body weight
and greater fat mass. Food intake was
unaffected in the Tg mice, but energy
expenditure was reduced. Overall, the
differences were consistent with reduced
fat oxidation in the Tg mice. However,
when the Tg mice were switched back to
normal chow, despite overexpression of
GHRL and MBOAT4, body weight and
energy expenditure differences disap-
peared, further supporting the notion that
preventing fat accumulation by blocking
ghrelin action is dependent upon dietary
composition.
This new work by Kirchner et al. adds
significantly to our understanding of the
conversion of DAG to active ghrelin
in vivo. The authors clearly show code-
pendence upon MBOAT4 and dietary
MCT substrate for the production of
active ghrelin. Although these new data
explain the lack of ghrelin production
during fasting, the spontaneous rhythmic
parallel rise and fall of both ghrelin and
DAG occurring during ad lib feeding
remains something of a mystery (Liu
et al., 2008). The data do, however, rein-
force the notion that circadian rhythmicity
is regulated by cephalic input and not
simply by ingestion of food. Studies in
humans have shown that, during the first
24 hr of a fast, under conditions in which
GOAT activity is likely reduced, the
rhythmic rise and fall of ghrelin and DAG
levels in the blood continues at declining
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more, when rats were allowed to see or
smell but not eat food, ghrelin and DAG
levels fell as if they had ingested food
(Seoane et al., 2007). This response was
blocked by atropine, suggesting that the
parallel rise and fall in circulating ghrelin
and DAG levels is likely controlled by
a cephalic cholinergic signal at customary
meal times, rather than by ingestion of
food.
It is exciting to anticipate the inclusion
of additional parameters into the model.
Future studies will undoubtedly include
quantitation of MBOAT4 protein for
making correlations with Mboat4 gene
expression, as well as a consideration of
increased GHS-R1a mRNA levels that
have been observed during fasting. As
with all good papers, the results beg
answers to new questions. Now that we
recognize the interdependence of GOAT
activity and dietary MCT substrates for
production of ghrelin, we must ask
how independent actions of DAG fit into
the puzzle? Administered centrally, DAGstimulates feeding by activating orexin
neurons, whereas ghrelin’s effect is
through NPY/AGRP neurons. How do
the ghrelin and DAG pathways comple-
ment each other? Is GOAT expressed in
ghrelin neurons of the CNS? Effects on
tissues that do not express GHS-R1a
have been described for active ghrelin
and DAG, but elucidation of these path-
ways awaits identification of the DAG
receptor.
Though questions remain, the new data
from Kirchner et al. (2009) refute the
popular belief that ghrelin production
is highest during fasting. The fact that
neither Mboat4 expression nor Ghrl
expression were augmented during fast-
ing also argues that ghrelin production is
not critical for generation of a hunger
signal.
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